<ul>
<li>3 家投资超过 1000 亿美元的顶级制药公司股票</li>
</ul>
<p>诺华制药 (NYSE:NVS - 免费报告) - Zacks Research 的投资分析师在 9 月 4 日星期四向投资者发布的报告中上调了诺华 2027 财年的每股收益 (EPS) 预期。Zacks Research 分析师团队现在预计该公司将实现每股收益 10.13 美元，高于之前预测的 10.08 美元。诺华当前全年的共识预期收益为每股 8.45 美元。</p>
<p>诺华 (NYSE:NVS - 获取免费报告) 最近在 7 月 17 日星期四发布了季度财报。该公司报告季度每股收益 (EPS) 为 2.42 美元，超出分析师共识预期的 2.38 美元，超过 0.04 美元。诺华的股本回报率为 41.08%，净利润率为 25.64%。该季度的收入为 140.5 亿美元，而分析师预期为 139.4 亿美元。在去年同期，该公司每股收益为 1.97 美元。与去年同期相比，该季度的收入增长了 12.3%。</p>
<ul>
<li>3 只可能在市场波动后飙升的动量股票</li>
</ul>
<p>其他一些股票分析师也对 NVS 发布了报告。摩根士丹利将诺华的评级从 “减持” 上调至 “持平”，并在 8 月 8 日星期五的研究报告中设定了 123.00 美元的目标价。德意志银行在 8 月 21 日星期四的研究报告中重申了对诺华股票的 “买入” 评级。最后，华尔街 Zen 在 8 月 22 日星期五的研究报告中将诺华的评级从 “强力买入” 下调至 “买入”。一位分析师给予该股票 “强力买入” 评级，一位给予 “买入” 评级，五位给予 “持有” 评级，两位给予 “卖出” 评级。根据 MarketBeat.com 的数据，诺华目前的共识评级为 “持有”，共识目标价为 124.33 美元。</p>
<p><strong>查看我们关于 NVS 的最新研究报告</strong></p>
<h2>诺华股票表现</h2>
<ul>
<li>制药领军企业盈利超预期，但股价下跌</li>
</ul>
<p>NYSE NVS 的股票在星期五开盘价为 128.49 美元。该股票的 50 日移动平均价格为 121.06 美元，200 日移动平均价格为 114.94 美元。该公司的债务与股本比率为 0.53，速动比率为 0.62，流动比率为 0.82。该公司的市值为 2714.1 亿美元，市盈率为 18.70，PEG 比率为 1.80，贝塔值为 0.63。诺华的 1 年最低价为 96.06 美元，1 年最高价为 129.21 美元。</p>
<h2>机构投资者对诺华的看法</h2>
<p>对冲基金和其他机构投资者最近对该公司的持仓进行了调整。GFG Capital LLC 在第二季度收购了诺华的新股份，价值约 26,000 美元。Nexus Investment Management ULC 在第一季度收购了诺华的新股份，价值约 25,000 美元。WPG Advisers LLC 在第一季度收购了诺华的新股份，价值约 25,000 美元。Tsfg LLC 在第一季度将其在诺华的股份增加了 366.0%。Tsfg LLC 现在拥有该公司 233 股股票，价值 26,000 美元，此前在此期间又购买了 183 股。最后，Legacy Investment Solutions LLC 在第二季度收购了诺华的新股份，价值约 30,000 美元。13.12% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于诺华</h2>
<p>(获取免费报告)</p>
<p>诺华制药 AG 从事医疗保健产品的研究、开发、生产和营销，业务遍及瑞士及国际市场。该公司为患者和医生提供处方药。其重点领域包括心血管、肾脏和代谢、免疫学、神经科学和肿瘤学，以及眼科和血液学。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票，胜过诺华</li>
<li>投资建筑股票</li>
<li>这就是 Oklo 与其他核创业公司的区别</li>
<li>3 只可以升级您投资组合的家居改善股票</li>
<li>为什么 Marvell 的 19% 下跌可能是一个重要的买入机会</li>
<li>股息之王宝洁在财报后疲软时值得买入</li>
<li>Daqo 新能源：太阳能垄断企业启动 1 亿美元的回购计划</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WUw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元于诺华吗？</h2>
<p>在您考虑诺华之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前买入……而诺华并不在名单上。</p>
<p>尽管诺华目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

诺华制药

<p>Zacks Research 将诺华制药 (NYSE:NVS) 的 2027 财年每股收益 (EPS) 预测从 10.08 美元上调至 10.13 美元。目前市场对诺华全年收益的共识预期为每股 8.45 美元。在其最新的季度财报中，诺华报告的每股收益为 2.42 美元，超过了 2.38 美元的预期，收入为 140.5 亿美元。分析师对该股票的评级各不相同，整体评级为 “持有”，目标价为 124.33 美元。诺华的股票开盘价为 128.49 美元，市值为 2714.1 亿美元</p>

<ul>
<li>3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家投资超过 1000 亿美元的顶级制药公司股票</li>
</ul>
</div><p>Novartis AG (NYSE:NVS - Free Report) - Investment analysts at Zacks Research increased their FY2027 earnings per share (EPS) estimates for shares of Novartis in a note issued to investors on Thursday, September 4th. Zacks Research analyst Team now expects that the company will earn $10.13 per share for the year, up from their prior forecast of $10.08. The consensus estimate for Novartis' current full-year earnings is $8.45 per share.</p>
<div class="lb-trans"><p>诺华制药 (NYSE:NVS - 免费报告) - Zacks Research 的投资分析师在 9 月 4 日星期四向投资者发布的报告中上调了诺华 2027 财年的每股收益 (EPS) 预期。Zacks Research 分析师团队现在预计该公司将实现每股收益 10.13 美元，高于之前预测的 10.08 美元。诺华当前全年的共识预期收益为每股 8.45 美元。</p>
</div><p>Novartis (NYSE:NVS - Get Free Report) last issued its quarterly earnings data on Thursday, July 17th. The company reported $2.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.38 by $0.04. Novartis had a return on equity of 41.08% and a net margin of 25.64%.The business had revenue of $14.05 billion during the quarter, compared to analyst estimates of $13.94 billion. During the same period in the prior year, the company posted $1.97 EPS. The business's revenue for the quarter was up 12.3% compared to the same quarter last year.</p>
<div class="lb-trans"><p>诺华 (NYSE:NVS - 获取免费报告) 最近在 7 月 17 日星期四发布了季度财报。该公司报告季度每股收益 (EPS) 为 2.42 美元，超出分析师共识预期的 2.38 美元，超过 0.04 美元。诺华的股本回报率为 41.08%，净利润率为 25.64%。该季度的收入为 140.5 亿美元，而分析师预期为 139.4 亿美元。在去年同期，该公司每股收益为 1.97 美元。与去年同期相比，该季度的收入增长了 12.3%。</p>
</div><ul>
<li>3 Momentum Stocks That Could Soar Post-Market Volatility</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只可能在市场波动后飙升的动量股票</li>
</ul>
</div><p>A number of other equities analysts have also issued reports on NVS. Morgan Stanley raised Novartis from an &#34;underweight&#34; rating to an &#34;equal weight&#34; rating and set a $123.00 price target for the company in a research note on Friday, August 8th. Deutsche Bank Aktiengesellschaft reiterated a &#34;buy&#34; rating on shares of Novartis in a research report on Thursday, August 21st. Finally, Wall Street Zen downgraded Novartis from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research report on Friday, August 22nd. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Novartis presently has a consensus rating of &#34;Hold&#34; and a consensus target price of $124.33.</p>
<div class="lb-trans"><p>其他一些股票分析师也对 NVS 发布了报告。摩根士丹利将诺华的评级从 “减持” 上调至 “持平”，并在 8 月 8 日星期五的研究报告中设定了 123.00 美元的目标价。德意志银行在 8 月 21 日星期四的研究报告中重申了对诺华股票的 “买入” 评级。最后，华尔街 Zen 在 8 月 22 日星期五的研究报告中将诺华的评级从 “强力买入” 下调至 “买入”。一位分析师给予该股票 “强力买入” 评级，一位给予 “买入” 评级，五位给予 “持有” 评级，两位给予 “卖出” 评级。根据 MarketBeat.com 的数据，诺华目前的共识评级为 “持有”，共识目标价为 124.33 美元。</p>
</div><p><strong>View Our Latest Research Report on NVS</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 NVS 的最新研究报告</strong></p>
</div><h2>Novartis Stock Performance</h2>
<div class="lb-trans"><h2>诺华股票表现</h2>
</div><ul>
<li>Pharma Leader Beats on Earnings, But Shares Fall</li>
</ul>
<div class="lb-trans"><ul>
<li>制药领军企业盈利超预期，但股价下跌</li>
</ul>
</div><p>Shares of NYSE NVS opened at $128.49 on Friday. The stock has a fifty day moving average price of $121.06 and a two-hundred day moving average price of $114.94. The company has a debt-to-equity ratio of 0.53, a quick ratio of 0.62 and a current ratio of 0.82. The firm has a market cap of $271.41 billion, a P/E ratio of 18.70, a PEG ratio of 1.80 and a beta of 0.63. Novartis has a 1 year low of $96.06 and a 1 year high of $129.21.</p>
<div class="lb-trans"><p>NYSE NVS 的股票在星期五开盘价为 128.49 美元。该股票的 50 日移动平均价格为 121.06 美元，200 日移动平均价格为 114.94 美元。该公司的债务与股本比率为 0.53，速动比率为 0.62，流动比率为 0.82。该公司的市值为 2714.1 亿美元，市盈率为 18.70，PEG 比率为 1.80，贝塔值为 0.63。诺华的 1 年最低价为 96.06 美元，1 年最高价为 129.21 美元。</p>
</div><h2>Institutional Investors Weigh In On Novartis</h2>
<div class="lb-trans"><h2>机构投资者对诺华的看法</h2>
</div><p>Hedge funds and other institutional investors have recently made changes to their positions in the business. GFG Capital LLC acquired a new stake in shares of Novartis in the second quarter valued at about $26,000. Nexus Investment Management ULC bought a new stake in shares of Novartis in the first quarter valued at about $25,000. WPG Advisers LLC bought a new stake in shares of Novartis in the first quarter valued at about $25,000. Tsfg LLC lifted its stake in shares of Novartis by 366.0% in the first quarter. Tsfg LLC now owns 233 shares of the company's stock valued at $26,000 after buying an additional 183 shares during the period. Finally, Legacy Investment Solutions LLC bought a new stake in shares of Novartis in the second quarter valued at about $30,000. 13.12% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近对该公司的持仓进行了调整。GFG Capital LLC 在第二季度收购了诺华的新股份，价值约 26,000 美元。Nexus Investment Management ULC 在第一季度收购了诺华的新股份，价值约 25,000 美元。WPG Advisers LLC 在第一季度收购了诺华的新股份，价值约 25,000 美元。Tsfg LLC 在第一季度将其在诺华的股份增加了 366.0%。Tsfg LLC 现在拥有该公司 233 股股票，价值 26,000 美元，此前在此期间又购买了 183 股。最后，Legacy Investment Solutions LLC 在第二季度收购了诺华的新股份，价值约 30,000 美元。13.12% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About Novartis</h2>
<div class="lb-trans"><h2>关于诺华</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.</p>
<div class="lb-trans"><p>诺华制药 AG 从事医疗保健产品的研究、开发、生产和营销，业务遍及瑞士及国际市场。该公司为患者和医生提供处方药。其重点领域包括心血管、肾脏和代谢、免疫学、神经科学和肿瘤学，以及眼科和血液学。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Novartis</li>
<li>Investing in Construction Stocks</li>
<li>Here's What Separates Oklo From the Rest of the Nuclear Startups</li>
<li>3 Home Improvement Stocks that Can Upgrade Your Portfolio</li>
<li>Why Marvell’s 19% Drop Could Be a Big Buy-the-Dip Opportunity</li>
<li>Dividend King Proctor &amp; Gamble Is A Buy On Post-Earnings Weakness</li>
<li>Daqo New Energy: Solar Monopoly Launches $100M Buyback</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过诺华</li>
<li>投资建筑股票</li>
<li>这就是 Oklo 与其他核创业公司的区别</li>
<li>3 只可以升级您投资组合的家居改善股票</li>
<li>为什么 Marvell 的 19% 下跌可能是一个重要的买入机会</li>
<li>股息之王宝洁在财报后疲软时值得买入</li>
<li>Daqo 新能源：太阳能垄断企业启动 1 亿美元的回购计划</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WUw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NYSE&amp;Symbol=NVS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Novartis Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元于诺华吗？</h2>
</div><p>Before you consider Novartis, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑诺华之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novartis wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前买入……而诺华并不在名单上。</p>
</div><p>While Novartis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管诺华目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Zacks Research 上调了诺华制药 2027 财年的每股收益预测